David S. Snyder

发表

Philadelphia chromosome‐positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature

M. Slovak, S. Forman, D. Snyder, 2005, American journal of hematology.

Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.

D. Findley, J. Doroshow, R. Krance, 1987, Blood.

High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.

A. Nademanee, G. M. Schmidt, D. Snyder, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.

A. Nademanee, J. Zaia, S. Forman, 1988, Transplantation.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

M. Slovak, C. Sawyers, D. Arber, 2003, Blood.

Lumbar puncture and subdural hygroma and hematomas in hematopoietic cell transplant patients

H. Openshaw, D. Snyder, J. Ressler, 2008, Bone Marrow Transplantation.

The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.

A. Nademanee, J. Niland, G. Somlo, 1995, Blood.

In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.

J. Niland, G. Somlo, K. Margolin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission.

A. Nademanee, M. Amylon, R. Hoppe, 1991, Blood.

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

M. Amylon, M. Slovak, R. Negrin, 1999, Leukemia.

Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.

K. Ness, L. Robison, S. Bhatia, 2004, Blood.

Chronic myelogenous leukemia, version 1.2015.

J. Radich, K. Gregory, Hema M Sundar, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

K. Gregory, Hema M Sundar, M. Deininger, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.

J. Rossi, Y. Wu, P. Swiderski, 1993, Blood.

Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).

J. Rossi, Y. Wu, S. Forman, 1999, Human gene therapy.

NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

J. Radich, B. D. Smith, Hema M Sundar, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities

M. Slovak, D. Arber, V. Bedell, 2003, Leukemia.

The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings.

M. Slovak, K. Chang, D. Arber, 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Treatment of chronic myelogenous leukemia with bone marrow transplantation.

D. Snyder, P. Mcglave, David S. Snyder, 1990, Hematology/oncology clinics of North America.

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

J. Radich, H. Kantarjian, K. Gregory, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Thalidomide as salvage therapy for chronic graft-versus-host disease.

J. Niland, R. Negrin, G. Somlo, 1995, Blood.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors.

A. Nademanee, D. Findley, R. Krance, 1987, Transplantation.

High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.

A. Nademanee, K. Margolin, G. M. Schmidt, 1992, Blood.

Fractionated total body irradiation and high dose cyclophosphamide: a preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission

L. R. Hill, P. Bierman, A. Nademanee, 1988, Blut: Zeitschrift für die Gesamte Blutforschung.

Allogeneic bone marrow transplantation for high risk non-hodgkin's lymphoma during first complete remission

P. Bierman, A. Nademanee, S. Forman, 1987, Blut.

NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

J. Radich, B. D. Smith, Hema M Sundar, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

ALLOGENEIC BONE MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA DURING FIRST COMPLETE REMISSION

L. R. Hill, A. Nademanee, D. Findley, 1987, Transplantation.

Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.

A. Nademanee, J. Niland, G. Somlo, 1997, Blood.

Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD

K. Chang, S. Forman, D. Senitzer, 2010, Bone Marrow Transplantation.

High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.

A. Nademanee, J. Niland, A. Krishnan, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.